Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Luis Puig, Jose Bernabeu-Wittel, Ignasi Gich, Monica Rios, María Teresa Montserrat-García, Eulalia Baselga, Fania Zamantta Muñoz-Garza, Esther Roé-Crespo
Publikováno v:
JAMA Dermatol
JAMA DERMATOLOGY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
JAMA Dermatology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
JAMA DERMATOLOGY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
JAMA Dermatology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
IMPORTANCE: Treatment of infantile hemangioma (IH) with topical timolol in the first 2 months of life (early proliferative phase) may prevent further growth and the need for treatment with oral propranolol. To our knowledge, no studies have determine
Autor:
Amit Maity, Alain H. Rook, Jennifer Villaseñor-Park, Carmela C. Vittorio, Kevin Zhang, Paul Haun, Sara A. Berg, Sara Samimi, Joanne Inverso, Daniel J. Lewis, Jaclyn Rosenthal, Christina A Del Guzzo, Ellen J. Kim, Maria Wysocka, Jessica E. Teague, Neha Jariwala, Bernice M. Benoit, Joseph S. Durgin, John P. Plastaras, Rachael A. Clark
Publikováno v:
JAMA Dermatol
Importance Sezary syndrome (SS) is an advanced form of cutaneous T-cell lymphoma with few long-term remissions observed. Objective To profile 3 patients with SS who have experienced long-term remission following the addition of low-dose total skin el
Autor:
Jake J. Lee, John S. Schneider, Dorina Kallogjeri, Jay F. Piccirillo, Murali M. Chakinala, Andrew M. Peterson
Publikováno v:
JAMA Otolaryngol Head Neck Surg
Importance Other than nasal moisturizers, no standard-of-care medical therapy exists for epistaxis in hereditary hemorrhagic telangiectasia (HHT). With epistaxis as the greatest cause of morbidity in patients with HHT, there is a need to identify eff
Autor:
Nina A. Karaseva, Sukrut Shah, Lucjan Wyrwicz, Joseph Chao, Christian Caglevic, Kohei Shitara, Luis Villanueva, Eric Van Cutsem, Al B. Benson, Eray Goekkurt, Wasat Mansoor, Marcelo Garrido, Iveta Kudaba, Keun Wook Lee, Jeeyun Lee, Maria Alsina, Andrew H. Ko, Charles S. Fuchs, S. Peter Kang, Josep Tabernero, Hugo Castro, Hironaga Satake, Uma Kher, Yung-Jue Bang, Maria Ignez Braghiroli, Peter C. Enzinger, Zev A. Wainberg, Hyun Cheol Chung
Publikováno v:
JAMA Oncology. 6:1571
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alo
Autor:
Martin Sökler, Ulrich Keller, Carsten Kobe, Bastian von Tresckow, Andreas Rosenwald, Stephan Mathas, Paul J Bröckelmann, Michael Fuchs, Jasmin Mettler, Julia Meissner, Peter Borchmann, Andrea Kerkhoff, Andreas Zimmermann, Stephanie Sasse, Wolfram Klapper, Helen Goergen, Rainer Ordemann, Andreas Engert, Matthias Bormann, Teresa V Halbsguth, Christian Baues, Andreas Hüttmann
Publikováno v:
JAMA Oncol
Importance In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in relapsed/refractory cHL but ha
Autor:
Ethan Basch, Antonia V. Bennett, Gita Thanarajasingam, Gisela Schwab, Lauren J. Rogak, Howard I. Scher, Amylou C. Dueck, Gina L. Mazza, Aaron Weitzman
Publikováno v:
JAMA Oncol
IMPORTANCE: Standard adverse event (AE) reporting in oncology clinical trials has historically relied on clinician grading, which prior research has shown can lead to underestimation of rates of symptomatic AEs. Industry sponsors are beginning to imp
Autor:
Natasha Flowers, Steven T. Bird, Donna Przepiorka, Barry W. Miller, Zebulin Kessler, Corinne Woods, Clara Kim, Tae-Hyun Jung, Bo Kim, Kate Gelperin, David J. Graham, Michael Wernecke, Thomas E. MaCurdy, Stephen McKean, Jeffrey A. Kelman, Rongrong Wang, Fang Tian
Publikováno v:
JAMA Oncol
Idelalisib (IDEL) is approved as monotherapy in relapsed follicular lymphoma (FL) and with rituximab (IDEL+R) for relapsed chronic lymphocytic leukemia (CLL). Toxic effects can be severe and treatment-limiting. Outcomes in a real-world population are
Autor:
Yeung-Chul Mun, James Larkin, Keith T. Flaherty, Edward McKenna, Brigitte Dréno, Qian Zhu, Antoni Ribas, Axel Hauschild, Paolo A. Ascierto, Karl D. Lewis, Grant A. McArthur
Publikováno v:
JAMA Oncology. 4:1382
Importance Prognostic models may provide insight into clinical trial results and inform the clinical management of patients withBRAFV600–mutated metastatic melanoma. Objective To identify subgroups with distinct survival outcomes based on clinical
Publikováno v:
JAMA Dermatology. 154:1221
This randomized clinical trial assesses whether treatment with the neurokinin 1 receptor antagonist aprepitant decreases pruritus vs placebo in patients with Sézary syndrome.
Autor:
Shandra Wilson, Seth P. Lerner, Lawrence Karsh, Robert S. Svatek, Philip C. Mack, Guan Wu, Jeffrey M. Holzbeierlein, Khaled S. Hafez, Melissa Plets, Edward M. Messing, Christopher P. Evans, Deepak M. Sahasrabudhe, Catherine M. Tangen, Daniel J. Culkin, Nicholas J. Vogelzang, David P. Wood, Ian M. Thompson, Timothy C. Brand, Theresa M. Koppie
Publikováno v:
JAMA. 319:1880
IMPORTANCE: Low-grade non–muscle-invasive urothelial cancer frequently recurs after excision by transurethral resection of bladder tumor (TURBT). OBJECTIVE: To determine whether immediate post-TURBT intravesical instillation of gemcitabine reduces